Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial

Hassan Seddik,Hanae Boutallaka,Ilham Elkoti,Fouad Nejjari,Reda Berraida,S Berrag,Khaoula Loubaris,Sara Sentissi,Ahmed Benkirane

Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial

2019

Hassan Seddik
Hanae Boutallaka
Ilham Elkoti
Fouad Nejjari
Reda Berraida
S Berrag
Khaoula Loubaris
Sara Sentissi
Ahmed Benkirane

Aim To determine the effect of Saccharomyces boulardii CNCM I-745 (S. boulardii) plus sequential therapy on Helicobacter pylori (H. pylori) eradication rate.

Keywords:

Sequential treatment
Anesthesia
Diabetes mellitus
Saccharomyces boulardii
Gastroenterology
Medicine
Helicobacter pylori
Helicobacter Pylori Infections
Internal medicine
open label
pharmacology toxicology
treatment compliance

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations